The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Long-term 5-year data continues to show RESPONSE to ruxolitinib in polycythemia vera
The 5-year efficacy and safety date from the Phase III RESPONSE study (NCT01243944) are discussed here by Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France. This study compared ruxolitinib with the best available therapy in hydroxyurea-resistant/intolerant polycythemia vera patients. This analysis, presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, consolidated the long-term clinical benefits of ruxolitinib.
